Veracyte said that the draft policy is open to a 45-day comment period and could potentially go into effect in early 2019.
The company said proceeds will be used for working capital, and may also be used to acquire or invest in complementary businesses or technologies.
Veracyte will offer 5 million shares at $10.25 per share. It has granted underwriters an option to purchase an additional 750,000 shares.
Veracyte anticipates that it can tap into the growing precision medicine market by leveraging its database of RNA sequencing data for thyroid and lung cancer.
The firm will use the proceeds for working capital, but said it may also acquire or invest in complementary technologies or businesses.
The firm beat analysts' consensus estimates on both the top and bottom lines, and it raised its 2018 annual revenue guidance.
The study demonstrates that Veracyte's new test improves upon an earlier version in its ability to identify thyroid nodules that are likely to be benign.
The Envisia test uses RNA sequencing and machine learning to diagnose idiopathic pulmonary fibrosis.
The company recognized $20 million in Q1 revenues and grew its testing volume by 18 percent.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.